scholarly journals Ganciclovir‐resistant post‐transplant cytomegalovirus infection due to combined deletion mutation at codons 595‐596 of the UL97 gene

2019 ◽  
Vol 21 (6) ◽  
Author(s):  
Po Yee Mia Leung ◽  
Thomas Tran ◽  
Adam Testro ◽  
Kathy Paizis ◽  
Jason Kwong ◽  
...  
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Minjae Yoon ◽  
Jaewon Oh ◽  
Kyeong-Hyeon Chun ◽  
Chan Joo Lee ◽  
Seok-Min Kang

AbstractImmunosuppressive therapy can decrease rejection episodes and increase the risk of severe and fatal infections in heart transplantation (HT) recipients. Immunosuppressive therapy can also decrease the absolute lymphocyte count (ALC), but the relationship between early post-transplant ALC and early cytomegalovirus (CMV) infection is largely unknown, especially in HT. We retrospectively analyzed 58 HT recipients who tested positive for CMV IgG antibody and received basiliximab induction therapy. We collected preoperative and 2-month postoperative data on ALC and CMV load. The CMV load > 1200 IU/mL was used as the cutoff value to define early CMV infection. Post-transplant lymphopenia was defined as an ALC of < 500 cells/μL at postoperative day (POD) #7. On POD #7, 29 (50.0%) patients had post-transplant lymphopenia and 29 (50.0%) patients did not. The incidence of CMV infection within 1 or 2 months of HT was higher in the post-transplant lymphopenia group than in the non-lymphopenia group (82.8% vs. 48.3%, P = 0.013; 89.7% vs. 65.5%, P = 0.028, respectively). ALC < 500 cells/μL on POD #7 was an independent risk factor for early CMV infection within 1 month of HT (odds ratio, 4.14; 95% confidence interval, 1.16–14.77; P = 0.029). A low ALC after HT was associated with a high risk of early CMV infection. Post-transplant ALC monitoring is simple and inexpensive and can help identify patients at high risk of early CMV infection.


2007 ◽  
Vol 22 (2) ◽  
pp. 245-249 ◽  
Author(s):  
En-Ling Leung Ki ◽  
Jean-Pierre Venetz ◽  
Pascal Meylan ◽  
Fréderic Lamoth ◽  
Juan Ruiz ◽  
...  

Blood ◽  
2021 ◽  
Author(s):  
Scott R Goldsmith ◽  
Muhammad Bilal Abid ◽  
Jeffery J. Auletta ◽  
Asad Bashey ◽  
Amer Beitinjaneh ◽  
...  

Prior studies suggest increased CMV infection following haploidentical donor transplantation with post-transplant cyclophosphamide (HaploCy). The role of allograft source and PTCy in CMV infection and disease is unclear. We analyzed the effect of graft source and PTCy on incidence of CMV infection as well as transplant outcomes as it relates to CMV serostatus and occurrence of CMV infection by d180. We examined patients reported to CIBMTR between 2012-2017 who had received HaploCy (n = 757), Sib with PTCy (SibCy, n=403), or Sib with calcineurin inhibitor-based prophylaxis (SibCNI, n=1605) for AML/ALL/MDS. Cumulative incidences of CMV infection by d180 were 42% (99% CI, 37-46), 37% (31 - 43), and 23% (20 - 26), respectively [p&lt;0.001]. CMV end-organ disease was statistically comparable. CMV infection risk was highest for CMV-Seropositive recipients (R+), but significantly higher in PTCy recipients regardless of donor [HaploCy (n=545): HR 50.3 (14.4 - 175.2); SibCy (n=279): HR 47.7 (13.3 - 171.4); SibCNI (n=1065): HR 24.4 (7.2 - 83.1); p&lt;0.001]. D+/R- patients also had increased risk for CMV infection. Among seropositive recipients or those developing CMV infection, HaploCy had worse OS and NRM. Relapse was unaffected by CMV infection or serostatus. PTCy was associated with lower chronic GVHD overall, but CMV infection in PTCy recipients was associated with higher cGVHD (p=0.006). PTCy, regardless of donor, is associated with higher incidence of CMV infection, augmenting the risk of seropositivity. Additionally CMV infection may negate the cGVHD protection of PTCy. This study supports aggressive prevention strategies in all patients receiving PTCy.


1993 ◽  
Vol 39 (1) ◽  
pp. 45-47 ◽  
Author(s):  
A Hausen ◽  
C Aichberger ◽  
A Königsrainer ◽  
G Weiss ◽  
R Margreiter ◽  
...  

Abstract Biliary neopterin concentrations were measured daily in nine liver-transplant recipients during the early post-transplant period (on average, 25 days). Concentrations increased strongly during rejection episodes and decreased quickly after successful antirejection therapy. Contrary to the changes of urinary neopterin, cytomegalovirus infection and hepatitis were not associated with an increase in biliary neopterin concentrations. Therefore, measurement of neopterin in bile fluid and in urine may aid in distinguishing rejection from infectious complications in liver-allograft recipients.


2009 ◽  
Vol 81 (3) ◽  
pp. 507-510 ◽  
Author(s):  
Jenna M. Iwasenko ◽  
Gillian M. Scott ◽  
William D. Rawlinson ◽  
Anne Keogh ◽  
Daniel Mitchell ◽  
...  

2020 ◽  
Vol 5 (12) ◽  
pp. 2228-2237
Author(s):  
Aniruddha Srivastava ◽  
Joshua Bodnar ◽  
Fauzia Osman ◽  
Margaret R. Jorgenson ◽  
Brad C. Astor ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document